What do the numbers say about Amrutanjan Health Care Limited (AMRUTANJAN)? Here's a look at its financials, valuation, and ownership data.
Amrutanjan Revenue Trend
Amrutanjan Health Care Limited's top line grew 7.3% to ₹452 Cr in FY2025, compared to ₹421 Cr in FY2024.
Over the past 10 years, revenue has grown at a healthy 10.5% CAGR, from ₹167 Cr to ₹452 Cr. That's solid, above-average growth.
With a top line of ₹452 Cr, Amrutanjan Health Care Limited operates at a smaller scale within the pharmaceuticals sector.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹452 Cr | +7.3% |
| FY2024 | ₹421 Cr | +6.9% |
| FY2023 | ₹394 Cr | -6.4% |
| FY2022 | ₹421 Cr | +26.6% |
| FY2021 | ₹333 Cr | — |
View Amrutanjan Health Care Limited's full 10-year revenue trend with CAGR analysis →
Amrutanjan Profitability
Amrutanjan Health Care Limited turned in a net profit of ₹50.8 Cr for FY2025. That's 13.0% better than the ₹45.0 Cr earned in FY2024.
The company squeezed out better margins in FY2025, with net margin at 11.3% versus 10.7% in FY2024.
Diluted EPS came in at ₹17.58 for FY2025, up from ₹15.56 a year earlier.
Is Amrutanjan Undervalued
Amrutanjan Health Care Limited shares are currently trading at ₹521.20.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Amrutanjan Shareholding Pattern
Promoters continue to hold 46.5% of the company, unchanged over recent quarters.
Foreign institutions moved their stake up to 2.4% from 2.4% over the past year.
The DII stake stands at 12.3% as of June 2026, versus 12.9% in the year-ago period.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 46.5% | 2.4% | 12.3% | 38.7% |
| Mar 2026 | 46.5% | 2.2% | 12.7% | 38.6% |
| Dec 2025 | 46.5% | 2.3% | 13.0% | 38.2% |
| Sep 2025 | 46.5% | 2.4% | 12.9% | 38.2% |
Track quarterly shareholding changes for Amrutanjan Health Care Limited →
Amrutanjan Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹4.21B (up 14.9% YoY from ₹3.67B).
Top categories: Other Assets (62.7%), Property, Plant & Equipment (14.7%), Receivables (13.2%).
Of the ₹4.21B in liabilities and equity, 77.5% is shareholder equity, 0.5% is interest-bearing debt, and 22.0% is operating liabilities. Over the year, debt is up 20.2% and equity is up 13.2%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 101.55M |
| Receivables | 558.22M |
| Inventories | 272.60M |
| Property, Plant & Equipment | 620.43M |
| Investments | 451,000 |
| Intangibles & Goodwill | 16.78M |
| Other Assets | 2.64B |
| Category | Value |
|---|---|
| Equity | 3.27B |
| Short-term Debt | 4.02M |
| Long-term Debt | 16.76M |
| Trade Payables | 690.43M |
| Other Liabilities | 236.52M |
Amrutanjan Key Highlights
Pulling it all together, here's what the numbers say about Amrutanjan Health Care Limited (AMRUTANJAN) heading into the next fiscal year.
Revenue of ₹452 Cr in FY2025, up 7.3% year-over-year.
Long-term revenue has been compounding at 10.5% annually over 10 years.
The company is profitable, with a net margin of 11.3% and net income of ₹50.8 Cr.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for Amrutanjan Health Care Limited includes three valuation models, decade-long financials, and insider activity.